Each company will obtain $7 million upfront and $2 million in commercialization-based payments.
Indevus Pharmaceuticals and Rottapharm Madaus granted Allergan’s Canadian affiliate rights to market Sanctura XR™ in that country in exchange for up to $9 million per firm.
Allergan already holds U.S. rights to this therapy through its acquisition of Esprit Pharmaceuticals. Additionally, Rottapharm Madaus previously obtained marketing licenses to Sanctura XR for the rest of the world, except Canada, Japan, Korea, and China. In these regions Indevus and Rottapharm Madaus had previously agreed to jointly license rights to third-party partners.
Under the terms of the current agreement, Allergan will pay each firm $7 million upfront and $2 million in sales threshold milestone payments. Allergan will be responsible for all regulatory and marketing activities in Canada.
“We are pleased to have licensed the Canadian rights for Sanctura XR to Allergan,” stated Glenn L. Cooper, M.D., chairman and CEO of Indevus. “This agreement further consolidates the rights for Sanctura XR within one highly competent organization. We continue to pursue opportunities to obtain marketing partners in Japan, Korea, and China, where we agreed to jointly license rights with Rottapharm Madaus.”
Sanctura XR is indicated for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. While the drug was sanctioned in the U.S. in August 2007, it has not yet been approved in Canada.
